Pharmaceutical industry – Page 29
-
BusinessWillow promises new medicines
Investigating tree’s metabolites throws up much more than aspirin
-
OpinionDrug pricing must be more transparent
Pricing is a complex issue - how can we make it clearer?
-
BusinessEuropean Commission to investigate excessive drug pricing
Inquiry covers claims that Aspen Pharma’s price rises on five cancer treatments were unjustified
-
BusinessSeattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
-
OpinionHow safe should drugs be?
What does spotting new risks in approved medicines say about how effective regulators are?
-
BusinessPatheon buyout brings Thermo into contract manufacturing
$7.2bn deal expands Thermo Fisher’s laboratory products and services segment
-
NewsLegal battles stall US biosimilars
Unclear legislation and lack of regulatory guidance means companies are turning to the courts
-
BusinessJ&J fights talc cancer claims
Firm has lost several court cases linking talc to ovarian cancer, but vows to appeal
-
BusinessMerck KGaA to buy Chematica
Retrosynthesis tool will gain computational muscle and integrate with Sigma–Aldrich catalogue
-
BusinessIndia probes Roche over biosimilars
Mylan and Biocon claim Roche abused its market dominance to quash generic breast cancer antibodies
-
BusinessBrexit raises regulatory worries
Risk of doubling legal burden for industry undermines referendum’s ‘red-tape cutting’ claims
-
BusinessChina approves BMS’s hepatitis C drugs
Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved
-
OpinionCrystal clear
The dark craft of crystallisation is an essential skill when working on kilogram scale
-
ResearchCatalyst puts chiral twist on phosphorus drugs
Simple molecule overcomes headache of phosphorus stereochemistry in antiviral drug synthesis
-
BusinessFresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
-
OpinionAlternate chemical realities
What would chemistry look like if key discoveries had happened differently?
-
BusinessHow do chemical firms last hundreds of years?
What distinguishes companies that thrive from others that failed?
-
BusinessJob cuts at Amgen, Takeda and Vertex
Takeda reorganising following Ariad takeover, while Amgen and Vertex move staff to Cambridge and San Francisco hubs
-
FeatureThe flow revolution
Continuous approaches are starting to find use in fine chemicals, as Angeli Mehta discovers
-
BusinessLilly loses arbitration over Canadian patents
Firm had sought recompense under the Nafta trade agreement